Exhaled Breath Condensate
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Small RNA Profiling in EBC in Athletes
A Community Study of the Risk for Obstructive Sleep Apnea and Respiratory Inflammation in an Adult Chinese Population
Aspergillosis Detection Via EBC-GM in Ventilated Patients
Prevention of CF Exacerbation in Childhood: PREVEC Study
"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and the Value in Follow-up
Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study
Evaluation of the Acute Effect of Water-Pipe Smoking on the Respiratory System